Last reviewed · How we verify
Research Maatschap Cardiologen Rotterdam Zuid — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Prasugrel based short DAPT | Prasugrel based short DAPT | marketed | ||||
| Prasugrel based standard DAPT | Prasugrel based standard DAPT | marketed | P2Y12 receptor antagonist (thienopyridine) | P2Y12 receptor | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Azienda Policlinico Umberto I · 1 shared drug class
- Deutsches Herzzentrum Muenchen · 1 shared drug class
- Elliot Israel, MD · 1 shared drug class
- Sanofi · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Research Maatschap Cardiologen Rotterdam Zuid:
- Research Maatschap Cardiologen Rotterdam Zuid pipeline updates — RSS
- Research Maatschap Cardiologen Rotterdam Zuid pipeline updates — Atom
- Research Maatschap Cardiologen Rotterdam Zuid pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Research Maatschap Cardiologen Rotterdam Zuid — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/research-maatschap-cardiologen-rotterdam-zuid. Accessed 2026-05-17.